Elliptic Laboratories AS (ELABS) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Elliptic Laboratories AS NOK 0.79, price NOK 3.60, upside -78.1%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Elliptic Laboratories AS for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 2.38 – kr 29.05 · fair‑value band kr 0.5200 – kr 0.9900 · the kr 3.60 price screens above the kr 0.7900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Elliptic Laboratories AS in your weekly email
Every Wednesday you see whether Elliptic Laboratories AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Elliptic Laboratories ASA, an artificial intelligence (AI) software company, engages in the provision of AI virtual smart sensors for the smartphone, laptop, Internet of Things, and automotive markets in Norway, the United States, China, South Korea, Taiwan, and Japan.
Show more
Elliptic Laboratories ASA, an artificial intelligence (AI) software company, engages in the provision of AI virtual smart sensors for the smartphone, laptop, Internet of Things, and automotive markets in Norway, the United States, China, South Korea, Taiwan, and Japan. The company offers AI Virtual Human Presence Sensor, a presence-detection solution used to improve the security of data stored on devices and to allow intuitive responses based on natural human interaction; AI Virtual Proximity Sensor that enables exquisite full-screen devices; and AI Virtual Connection Sensor that allows pair and authenticate smart devices that are in the same room using ultrasound. It also provides AI Virtual Position Sensor which automatically detects the location of an external display in relation to a laptop; AI Virtual Gesture Sensor that enables touchless user interactions; AI Virtual Breathing sensor that enables to track person's breathing; and AI Virtual heartbeat Sensor that tracks a person's heart rate. The company was incorporated in 2006 and is headquartered in Oslo, Norway.
Stock analysis
Elliptic Laboratories AS (ELABS) currently trades at kr 3.60, while our model-based Fair Value estimate is kr 0.7900, implying the stock looks roughly 355.8% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: kr 0.5200 (bear) to kr 0.9900 (bull), the price of kr 3.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Technology sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Elliptic Laboratories AS reported revenue of 101M NOK in FY2025 versus 54.6M NOK in FY2021, a compound +16.7%/yr. Reported net income was −138M NOK in FY2025.
Key figures
Market cap 379M NOK (≈ $39.8M) · P/S ratio 3.79 · EPS (TTM) kr −1.42 · Net margin −136% · Return on equity −56.4% · Return on assets (EBIT) −9.7% · Operating margin −86.0% · Revenue (TTM) 91.6M NOK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 51% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −19% fair-value upside, at −78%, ELABS screens richer than that median.
Fair Value models
Bear kr 0.5200Fair Value kr 0.7900Bull kr 0.9900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−23.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.4% (2020) → −44.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Elliptic Laboratories AS with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Infrastructure · 383 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−76% · Bottom 25%
Profitability
Return on assets−11% · Bottom 25%
Net margin (TTM)−164% · Bottom 25%
Operating margin (TTM)−86% · Bottom 25%
Growth and dividend
Revenue growth−37% · Bottom 25%
Valuation Multiplesvs Software - Infrastructure median · lower = cheaper
P/B0.19× · Cheapest 25%
P/S (TTM)0.40× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)0· sector 48
PAST (return on equity)0· sector 18
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Elliptic Laboratories AS Fair Value". https://www.fairvalue-calculator.com/stock/ELABS
Frequently asked questions
Is Elliptic Laboratories AS (ELABS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 0.7900 versus a price of kr 3.60, about −78% upside (overvalued).
What is the fair value of ELABS?
Our model-based fair value for Elliptic Laboratories AS is kr 0.7900 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 3.60.
What is the quality score of ELABS?
Elliptic Laboratories AS has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elliptic Laboratories AS (ELABS)?
Our model-based price target is the fair value of kr 0.7900 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario kr 0.5200, optimistic scenario kr 0.9900. It is a calculation from audited fundamentals, not an analyst target.
What is the Elliptic Laboratories AS stock forecast for 2026?
Our models put fair value at kr 0.7900, about −78% upside versus a price of kr 3.60 (overvalued). Cautious scenario kr 0.5200, optimistic scenario kr 0.9900. The calculation is refreshed regularly with new filings.
What is the revenue of Elliptic Laboratories AS (ELABS)?
Elliptic Laboratories AS reported trailing-twelve-month revenue of about 91.6M NOK (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Elliptic Laboratories AS (ELABS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elliptic Laboratories AS it is kr 0.7900 per share (as of Sep 24, 2026), against a price of kr 3.60. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Elliptic Laboratories AS stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ELABS trades above its calculated fair value: price kr 3.60, fair value kr 0.7900, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELABS?
No. The price is what the market pays today (kr 3.60); the fair value is what the company's own numbers justify (kr 0.7900). For Elliptic Laboratories AS the two are kr 2.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elliptic Laboratories AS worth?
The market values Elliptic Laboratories AS at about 379M NOK (market capitalisation, as of Sep 24, 2026). Per share that is kr 3.60; our models calculate a fair value of kr 0.7900 per share.
What do the bullish and bearish scenarios say about ELABS?
Our models span a range for Elliptic Laboratories AS: cautious scenario kr 0.5200, base kr 0.7900, optimistic kr 0.9900 per share (as of Sep 24, 2026, price kr 3.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Elliptic Laboratories AS (ELABS)?
Balance-sheet figures for Elliptic Laboratories AS (as of Sep 24, 2026): return on equity −56.4%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is ELABS from its 52-week high?
Elliptic Laboratories AS trades at kr 3.60, about 64% below its 52-week high of kr 10.10 and 51% above the low of kr 2.38 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.7900 is for.
Which stocks are comparable to Elliptic Laboratories AS?
From the same area (Technology) we also value Microsoft Corporation, Oracle Corporation, Palantir Technologies Inc, Palo Alto Networks, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elliptic Laboratories AS stock attractive at the current price?
The data as of Sep 24, 2026: price kr 3.60, calculated fair value kr 0.7900 (−78%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELABS calculated?
We run Elliptic Laboratories AS through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.7900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Elliptic Laboratories AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elliptic Laboratories AS (ELABS)?
The closing price on Sep 24, 2026 was kr 3.60. Our model-based fair value is kr 0.7900, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elliptic Laboratories AS right now?
The price sits above even our optimistic bull case (kr 0.9900). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 0.5200 to kr 0.9900) leaves room in how you read the outcome.
Key figures of Elliptic Laboratories AS
How large is the market capitalisation of Elliptic Laboratories AS (ELABS)?
The market capitalisation of Elliptic Laboratories AS is 379M NOK (≈ $39.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elliptic Laboratories AS (ELABS)?
The price-to-sales ratio of Elliptic Laboratories AS is 3.79 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elliptic Laboratories AS (ELABS)?
Earnings per share at Elliptic Laboratories AS are kr −1.42. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Elliptic Laboratories AS (ELABS)?
The net margin of Elliptic Laboratories AS is −136% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Elliptic Laboratories AS (ELABS)?
The return on equity (ROE) of Elliptic Laboratories AS is −56.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elliptic Laboratories AS (ELABS)?
On an EBIT basis the return on assets of Elliptic Laboratories AS is −9.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elliptic Laboratories AS (ELABS)?
The operating margin of Elliptic Laboratories AS is −86.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elliptic Laboratories AS (ELABS)?
Revenue at Elliptic Laboratories AS is growing −36.6% versus a year earlier (3y avg +24.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Elliptic Laboratories AS (ELABS) generate?
The free cash flow of Elliptic Laboratories AS is −41.1M NOK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Elliptic Laboratories AS (ELABS) hold?
Elliptic Laboratories AS holds more cash than debt, 57.0M NOK net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Elliptic Laboratories AS in the live analysis
One click puts Elliptic Laboratories AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
